479 related articles for article (PubMed ID: 16088966)
1. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
4. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
5. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
[TBL] [Abstract][Full Text] [Related]
7. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors.
Scheie D; Andresen PA; Cvancarova M; Bø AS; Helseth E; Skullerud K; Beiske K
Am J Surg Pathol; 2006 Jul; 30(7):828-37. PubMed ID: 16819324
[TBL] [Abstract][Full Text] [Related]
11. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral distribution of 1p loss in oligodendroglial tumors.
Kros JM; van der Weiden M; Zheng PP; Hop WC; van den Bent MJ; Kouwenhoven MC
J Neuropathol Exp Neurol; 2007 Dec; 66(12):1118-23. PubMed ID: 18090920
[TBL] [Abstract][Full Text] [Related]
13. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
14. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
15. Can morphology predict 1p/19q loss in oligodendroglial tumours?
Scheie D; Cvancarova M; Mørk S; Skullerud K; Andresen PA; Benestad I; Helseth E; Meling T; Beiske K
Histopathology; 2008 Nov; 53(5):578-87. PubMed ID: 18983467
[TBL] [Abstract][Full Text] [Related]
16. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
18. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
[TBL] [Abstract][Full Text] [Related]
19. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
Kim SH; Kim H; Kim TS
Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
[TBL] [Abstract][Full Text] [Related]
20. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
Jha P; Agarwal S; Pathak P; Srivastava A; Suri V; Sharma MC; Chosdol K; Srivastava T; Gupta D; Gupta A; Suri A; Sarkar C
Cancer Genet Cytogenet; 2010 Apr; 198(2):126-34. PubMed ID: 20362227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
